Breaking News

Biogen Appoints Value-Based Medicine VP

May 12, 2014

Rudick bring expertise in MS programs

Richard (Rick) A. Rudick, M.D., has been appointed vice president of Development Sciences, Value-Based Medicine, at Biogen Idec. He reports to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.
 
Dr. Rudick will lead the newly created Value-Based Medicine Group that focuses on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). The group emphasizes more evidence-based, individualized treatment options with the goal of improving care.   
 
Dr. Rudick has played key roles in several MS clinical trials, including the trials of Biogen’s products AVONEX (interferon beta-1a) and TYSABRI (natalizumab). Dr. Rudick joins the company from the Cleveland Clinic, where he served as director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years.
 
“Rick has been a valued partner of the company for more than two decades. Through his years of hands-on clinical experience, he has gained a truly unique understanding of the needs of MS patients,” said Dr. Sandrock. “His vision, expertise and passion bolsters our efforts to create real-world, practical solutions to empower better decision-making and improve the way people live with MS.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016